Sigyn Therapeutics annual stock-based compensation
2017
2018
2020
2022
2023
2024
Sigyn Therapeutics Stock-Based Compensation Growth & History (SIGY)
Sigyn Therapeutics's stock-based compensation was $150,000 for fiscal 2024.
View full Sigyn Therapeutics company overviewSigyn Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $150,000 | −$65,558 | −30.41% |
| 2023 | 2023-12-31 | $215,558 | $215,558 | — |
| 2022 | 2022-12-31 | $0 | — | — |
| 2020 | 2020-12-31 | $0 | — | — |
| 2018 | 2018-12-31 | $114,978 | −$804,592 | −87.50% |
| 2017 | 2017-12-31 | $919,570 | — | — |
Sigyn Therapeutics quarterly stock-based compensation
Q1.17
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q4.19
Q1.20
Q2.20
Q3.20
Q4.22
Q1.23
Q2.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | $50,000 | $12,500 | +33.33% |
| Q2 2025 | 2025-06-30 | $50,000 | $12,500 | +33.33% |
| Q1 2025 | 2025-03-31 | $50,000 | $12,500 | +33.33% |
| Q4 2024 | 2024-12-31 | $37,500 | −$65,558 | −63.61% |
| Q3 2024 | 2024-09-30 | $37,500 | $0 | 0.00% |
| Q2 2024 | 2024-06-30 | $37,500 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $37,500 | $0 | 0.00% |
| Q4 2023 | 2023-12-31 | $103,058 | — | — |
| Q2 2023 | 2023-09-30 | $37,500 | — | — |
| Q1 2023 | 2023-06-30 | $37,500 | — | — |
| Q4 2022 | 2023-03-31 | $37,500 | — | — |
| Q3 2020 | 2020-09-30 | $0 | — | — |
| Q2 2020 | 2020-06-30 | $16,333 | — | — |
| Q1 2020 | 2020-03-31 | $26,917 | — | — |
| Q4 2019 | 2019-12-31 | $0 | −$2,685 | — |
| Q4 2018 | 2018-12-31 | $2,685 | — | — |
| Q3 2018 | 2018-09-30 | $32,370 | $31,770 | +5295.00% |
| Q2 2018 | 2018-06-30 | $58,392 | — | — |
| Q1 2018 | 2018-03-31 | $21,531 | −$24,460 | −53.18% |
| Q3 2017 | 2017-09-30 | $600 | — | — |
| Q1 2017 | 2017-03-31 | $45,991 | — | — |
Sigyn Therapeutics stock-based compensation trends
Between the periods ended 2017-12-31 and 2024-12-31, Sigyn Therapeutics's stock-based compensation decreased from $919,570 to $150,000, a change of −$769,570. The latest reported quarter, Q3 2025, shows $50,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sigyn Therapeutics source filings ↗